期刊
CANCER SCIENCE
卷 113, 期 2, 页码 597-608出版社
WILEY
DOI: 10.1111/cas.15210
关键词
apoptosis; BCL2 family proteins; mouse models; myeloproliferative neoplasms
类别
资金
- National Institutes of Health [R01CA240257]
- American Cancer Society [RSG-13-047]
- Harvard Stem Cell Institute Blood Program [DP-0110-12-00]
- Uehara Memorial Foundation
- Brazilian National Research Council -CNPQ [237730/2012]
- Sao Paulo Research Foundation -FAPESP [2011/11822-6, 2015/21866-1]
Research suggests that targeting Bcl-xL, overexpressed in JAK2V617F-driven myeloproliferative neoplasms, may be a therapeutic option. Knockout of Bcl-xL can alleviate MPN-induced anemia and thrombocytopenia independently of JAK2 mutation status. Disruption of Bcl2 balance with obatoclax shows cytotoxicity in JAK2V617F cell models and reduces clonogenic capacity in bone marrow cells, offering a potential treatment option for controlling myeloid expansion in the disease.
Several lines of research suggest that Bcl-xL-mediated anti-apoptotic effects may contribute to the pathogenesis of myeloproliferative neoplasms driven by JAK2V617F and serve as therapeutic target. Here, we used a knock-in JAK2V617F mouse model and confirmed that Bcl-xL was overexpressed in erythroid progenitors. The myeloproliferative neoplasm (MPN)-induced phenotype in the peripheral blood by conditional knock-in of JAK2V617F was abrogated by conditional knockout of Bcl2l1, which presented anemia and thrombocytopenia independently of JAK2 mutation status. Mx1-Cre Jak2V617(W/VF)/Bcl2l1(f/f) mice presented persistent splenomegaly as a result of extramedullary hematopoiesis and pro-apoptotic stimuli in terminally differentiated erythroid progenitors. The pan-BH3 mimetic inhibitor obatoclax showed superior cytotoxicity in JAK2V617F cell models, and reduced clonogenic capacity in ex vivo assay using Vav-Cre Jak2V617F bone marrow cells. Both ruxolitinib and obatoclax significantly reduced spleen weights in a murine Jak2V617F MPN model but did not show additive effect. The tumor burden reduction was observed with either ruxolitinib or obatoclax in terminal differentiation stage neoplastic cells but not in myeloid-erythroid precursors. Therefore, disrupting the BCL2 balance is not sufficient to treat MPN at the stem cell level, but it is certainly an additional option for controlling the critical myeloid expansion of the disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据